245 related articles for article (PubMed ID: 33210795)
1. Molecular Profiling of Exceptional Responders to Cancer Therapy.
Bilusic M; Girardi D; Zhou Y; Jung K; Pei J; Slifker M; Chen Q; Meerzaman D; Alpaugh K; Young D; Flieder D; Gray P; Plimack E
Oncologist; 2021 Mar; 26(3):186-195. PubMed ID: 33210795
[TBL] [Abstract][Full Text] [Related]
2. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.
Conley BA; Staudt L; Takebe N; Wheeler DA; Wang L; Cardenas MF; Korchina V; Zenklusen JC; McShane LM; Tricoli JV; Williams PM; Lubensky I; O'Sullivan-Coyne G; Kohn E; Little RF; White J; Malik S; Harris LN; Mann B; Weil C; Tarnuzzer R; Karlovich C; Rodgers B; Shankar L; Jacobs PM; Nolan T; Berryman SM; Gastier-Foster J; Bowen J; Leraas K; Shen H; Laird PW; Esteller M; Miller V; Johnson A; Edmondson EF; Giordano TJ; Kim B; Ivy SP
J Natl Cancer Inst; 2021 Jan; 113(1):27-37. PubMed ID: 32339229
[TBL] [Abstract][Full Text] [Related]
3. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature.
Nishikawa G; Luo J; Prasad V
Eur J Cancer; 2018 Sep; 101():143-151. PubMed ID: 30059818
[TBL] [Abstract][Full Text] [Related]
5. Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine.
Tsimberidou AM; Said R; Staudt LM; Conley BA; Takebe N
Cancer J; 2019; 25(4):296-299. PubMed ID: 31335394
[TBL] [Abstract][Full Text] [Related]
6. Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.
Levin MK; Wang K; Yelensky R; Cao Y; Ramos C; Hoke N; Pippen J; Blum JL; Brooks B; Palmer G; Palma N; Balasubramanian S; Ross JS; O'Shaughnessy J
Cancer Med; 2015 Aug; 4(8):1289-93. PubMed ID: 25871911
[TBL] [Abstract][Full Text] [Related]
7. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
[TBL] [Abstract][Full Text] [Related]
8. Transforming Biomarker Development with Exceptional Responders.
Jonsson P; Taylor BS
Trends Cancer; 2018 Jan; 4(1):3-6. PubMed ID: 29413420
[TBL] [Abstract][Full Text] [Related]
9. What have we learned from exceptional tumour responses?: Review and perspectives.
Mehra N; Lorente D; de Bono JS
Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
[TBL] [Abstract][Full Text] [Related]
10. Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.
Kamath S; Roopkumar J; Ni Y; Shen M; Bejarano P; Allende D; Nagarajan A; Nguyen T; Dergham B; Shepard D; Shapiro MA; McNamara MJ; Estfan BN; Nair KG; Khorana AA
Oncology (Williston Park); 2023 Dec; 37(12):488-495. PubMed ID: 38133563
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients.
Omarini C; Bettelli S; Caprera C; Manfredini S; Caggia F; Guaitoli G; Moscetti L; Toss A; Cortesi L; Kaleci S; Maiorana A; Cascinu S; Conte PF; Piacentini F
Cancer Biol Ther; 2018; 19(10):879-886. PubMed ID: 30067438
[TBL] [Abstract][Full Text] [Related]
12. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
13. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
15. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
Groisberg R; Hong DS; Roszik J; Janku F; Tsimberidou AM; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer Ther; 2018 Jul; 17(7):1595-1601. PubMed ID: 29654067
[TBL] [Abstract][Full Text] [Related]
16. The possibility of clinical sequencing in the management of cancer.
Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
[TBL] [Abstract][Full Text] [Related]
17. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
18. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
[TBL] [Abstract][Full Text] [Related]
19. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Exceptional or Super Responders to Cancer Drugs.
Prasad V; Vandross A
Mayo Clin Proc; 2015 Dec; 90(12):1639-49. PubMed ID: 26546106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
